Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Challenges, Opportunities For Cardinal In China Policy Change

Executive Summary

Major US pharma distributor Cardinal Health is further expanding its regional presence in China, with the country’s rapidly changing operating environment presenting opportunities and challenges.

You may also be interested in...



DTP Pharmacies March On In China: Pharma Ignores At Its Own Risk

A shift in dispensing from hospitals to external pharmacies has led to predictions that the direct-to-patient sales model will be big in China. But only those with the right partnerships and expertise will reap the benefits, leading pharmacy chain executives told a recent conference.

China’s Spreading Sunshine Policy Takes On Bloated Drug Receipts

Manipulation of China’s “fapiao”, or receipt system, is not new but now the State Council is cracking down on the practice, aiming to bring down inflated drug prices. Meanwhile, several provinces are cutting wholesale layers in a wider campaign to squeeze price inflation out of the commercial pharma segment.

Three Years, Seven Acquisitions Later, Cardinal Health Has More Plans In China

U.S. distributor Cardinal Health goes full speed ahead in China. It has bought local players to tap into the regional market, doubled direct-to-patient pharmacies, and provided pharmacy management services to large hospitals among endeavors in the past three and a half years with more to come.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC097047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel